Strong second quarter shows GSK reforms paying off
Markets have reacted warmly to GlaxoSmithKline’s (LSE: GSK) second quarter 2019 results statement, lifting the value of shares in the British drugmaker half a percentage point on the London Stock Exchange.
With overall group sales coming in at £7.8 billion ($9.75 billion), the pharmaceuticals business took in £4.3 billion, an increase of 2% from the comparable period of 2018.
GSK managed to beat analysts’ expectations for sales, partly due to demand for its highly successful shingles vaccine, Shingrix (zoster vaccine), and despite the loss of exclusivity for key respiratory product Advair (fluticasone/salmeterol).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze